












Subclinical hypothyroidism (SCH) is a form of 
mild thyroid failure and is a commonly encountered 
condition in clinical practice.  It denotes the presence 
of a raised serum thyroid stimulating hormone (TSH) 
and normal serum free thyroid hormone 
concentrations (tri-iodothyronine [T3] and thyroxine 
[T4]).  ‘Mild’ subclinical hypothyroidism is 
associated with a TSH level between 4.5-9mIU/L 
(0.4-4.2) whereas patients with a serum TSH level 
≥10mIU/L are classified as having the ‘severe’ form.  
The clinical significance of this condition has aroused 
a lot of interest over the last decade, especially its 
effects on various health outcomes (namely 
cardiovascular disease, lipid metabolism, fertility, 
pregnancy outcomes and fetal neurocognitive 
function). 
Unfortunately the unavailability of adequately 
powered, double-blind randomised controlled studies 
precludes the availability of clear cut guidelines as to 
how one should treat subclinical hypothyroidism.  
This review looks at the available evidence for and 
against treatment of SCH with levothyroixine. Most 
authors agree on the use of clinical judgement as well 
as individualising management based on the 
underlying unique patient characteristics when it 
comes to formulating a management plan for this 
condition.  
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The term subclinical hypothyroidism (SCH) is 
used to describe the finding of a raised serum thyroid 
stimulating hormone (TSH) level above the defined 
upper limit of a reference range in conjunction with 
normal concentrations of free thyroid hormones 1-3.  
By virtue of its very nature and due to the fact that 
patients with SCH exhibit few or no signs or 
symptoms of thyroid failure the diagnosis is a 
biochemical one. Thus, detection of SCH relies 
critically on the upper limit of the TSH reference 
range. Over the past few decades, the emergence of 
increasingly sensitive 3rd generation TSH 
immunometric assays have revolutionised thyroid 
testing, such that the upper reference limit has 
declined from about 10mIU/L to around 4.0-
4.5mIU/L1,4-5. This reflects improved functional 
sensitivity and specificity of the immunometric assays 
used, the recognition that normal TSH values are log 
distributed and also improvements in the sensitivity 
and specificity of the thyroid antibody tests used to 
pre-screen subjects. In fact the third National Health 
and Nutrition Examination Survey (NHANES III),6 
specified a serum TSH range of 0.45-4.5mIU/L using 
the 2.5th -97.5th percentiles, however there are still 
controversies regarding the upper normal limit. The 
National Academy of Clinical Biochemistry, for 
example, has indicated that 95% of euthyroid 
volunteers have a serum TSH level of between 0.4-
2.5mIU/L and thus argue that the upper TSH limit 
should be decreased to 2.5mIU/L.1 Of course this is 
not without repercussions as lowering the upper limit 
for normal serum TSH values would increase the 
number of patients diagnosed with SCH and the 
economic burden of therapy as well as the possibility 
of overtreatment. Moreover, there are no studies to 
suggest that patients with a serum TSH of between 2.5 
and 4.5mIU/L are at increased cardiovascular 
morbidity and mortality. These patients are at the very 
earliest stage of hypothyroidism and that apart from 
appropriate follow-up there is no compelling evidence 
stating the benefits of thyroxine treatment in such 
cases.5 Thus the American Thyroid Association and 
the American Association of Clinical Endocrinology 
(ATA/AACE) guidelines advise that when reference 
ranges of 3rd generation TSH assays are not available, 
the clinician should use the NHANESIII reference 
population range.1  
 
Review of the risks and/or benefits of thyroxine 
treatment in ‘mild’ subclinical hypothyroidism 
 
Rachel Agius  
Rachel Agius MD MRCP (UK) 
Department of Medicine, 












Malta Medical Journal    Volume 25 Issue 04 2013                                                                  29                                              
 
 
Prevalence and Aetiology 
The prevalence of SCH varies between 4 and 
20% of the adult population.  This wide range reflects 
differences among the population studied with respect 
to age, race, gender, dietary iodine intake as well as 
the TSH cut off value used to define SCH.3,7 In the 
Colorado study (which defined SCH as serum TSH 
>5.1mU/L), serum TSH concentrations were elevated 
in 9.5% of subjects, and it was found that this 
percentage increased with each decade of age in 
women but not in men. 3,9-11 
Around 60-80% of subjects with SCH have 
positive thyroid peroxidase antibodies making chronic 
autoimmune thyroiditis the commonest cause of SCH 
in iodine-replete communities.9 It has also been 
shown that obese individuals, healthy elderly patients 
and the white population have higher serum TSH 
levels and this should be taken into consideration 
when interpreting thyroid function tests in these 
cohorts of patients.3-4,7, 9,13 Thus, several authors 
recommend that serum TSH measurement should be 
repeated within 3 to 6 months after initial assessment 
(together with a free thyroxine [T4] level) in order to 
confirm the presence of a raised TSH level.2-3,9 
It has been necessary to categorise SCH as either 
‘mild’ in patients who have serum TSH levels of 
between 4.5-10mIU/L, and ‘severe’ if patients have a 
serum TSH of >10mIU/L.2,7-8 This is important for a 
number of reasons.  Patients with the severe form of 
SCH are at an increased risk of progressing to overt 
hypothyroidism, are more likely to be symptomatic 
and more likely to have adverse cardiovascular end 
points such as coronary heart disease, congestive heart 
failure and cardiovascular mortality.7,14-16  In view of 
this, treatment with levothyroxine is generally 
recommended for patients with serum TSH levels 
10mIU/L.3,7 However, review of the literature shows 
conflicting data with regards to evaluation and 
management of mild SCH. While it is known that the 
majority of patients will have the mild form of SCH7,9-
10 and that thyroid hormone action has major effects 
on the cardiovascular system as well as lipids and 
other tissues 4, the available data shows conflicting 
results with respect to management of mild 
SCH.2,4,7,9,11 These inconsistencies stem from the fact 
that the diagnosis of SCH is arbitrary, with different 
studies varying in their definition of SCH resulting in 
a wide degree of thyroid failure examined as well as 
heterogeneity with respect to age, gender and 
ethnicity of the examined subjects 8. Thus several 
authors and expert panels recommend using clinical 
judgement as well as an individualised approach, 
taking into account the individual’s unique situation 
when it comes to deciding the need for treatment of 
this condition.1 
 
Natural history and progression of subclinical 
hypothyroidism 
Both spontaneous recovery as well as 
progression towards overt hypothyroidism have been 
documented in several studies in patients with mildly 
raised serum TSH.  The presence of antithyorid 
antibodies, female sex as well as higher serum TSH 
levels (≥10mIU/L) are associated with increased risk 
of progression.3,4,18-19 In the 20 year follow-up of the 
Whickham study, the annual rate of progression to 
overt hypothyroidism was around 4% in females with 
a raised serum TSH level and positive antibodies, 3% 
if only serum TSH levels were raised and 2% in those 
with only positive antithyroid antibodies.  At the 20-
year follow up the respective cumulative rates of 
hypothyroidism were 55%, 33% and 27%.15,20  On the 
other hand another study showed that in subjects older 
than 55 years with SCH and no previous history of 
thyroid disease. 37.4% of patients normalized their 
serum TSH level and only 26.8% developed overt 
hypothyroidism, with the only significant factor for 
progression to overt hypothyroidism being the serum 
TSH concentration. 18 These findings consolidate our 
knowledge that whilst some subjects do progress to 
overt hypothyroidism, a significant number will not 
and hence obviate the need for T4 treatment.   
Subclinical hypothyroidism and its effects on 
cardiovascular disease and metabolism 
The various effects of thyroid hormone on the 
cardiovascular system and metabolism are well 
known and hence it is reasonable to expect adverse 
cardiovascular effects in patients with SCH.14 SCH 
has been associated with increased systemic vascular 
resistance, altered endothelial function, 
atherosclerosis, arterial stiffness, dyslipidaemia and 
altered coagulability. However, the association 
between SCH and coronary heart disease (CHD) 
events remain to be debated due to the divergent 
results of several observational studies.3,12,14,21-23 The 
Rotterdam study found that SCH was an independent 
risk factor for aortic atherosclerosis and myocardial 
infarction and the risk was comparable to the known 
major risk factors for cardiovascular disease (such as 
smoking, diabetes and dyslipidaemia).7,21   Also, a 
recent re-analysis of the original Whickham Survey 
(which defined SCH as a serum TSH between 6-
15mIU/L and normal T4 levels) showed a positive 
association between SCH and the risk of CHD events 
and mortality and  also suggests that treatment with 
thyroxine may reduce mortality as well as CHD 
events.  A meta analyses has suggested that the 
incidence and prevalence of CHD events and 
mortality were modestly increased in participants with 
mild thyroid failure younger than 65 years of age but 
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was higher in both genders, it was statistically 
significant only in women.24 Thus, it can be inferred 
that SCH is associated with an increased risk of CHD 
events and mortality particularly in those patients with 
a TSH concentration of 10mIU/L or greater.  
Another important feature of SCH is its effects 
on cardiac function.  SCH is associated with impaired 
left ventricular diastolic function at rest (often the 
earliest manifestation of heart disease in this setting) 
and systolic dysfunction on effort which may be 
associated with poor exercise capacity and impaired 
quality of life.7,9,25  In the Cardiovascular Health 
Study of 3044 adults aged ≥ 65 years of age, an 
increased incidence of heart failure was only recorded 
in those patients with a TSH of ≥10mIU/L.19 This risk 
was not increased in older subjects with TSH levels 
between 4.5 and 9.9mIU/L.  Studies evaluating 
reversibility of cardiac dysfunction following 
levothyroxine therapy were positive suggesting that 
thyroxine therapy can normalise the hemodynamic 
alterations due to SCH, however, most of them were 
not blinded or placebo-controlled.3,12 
The metabolic abnormalities linked with SCH 
include an increase in total and LDL cholesterol, but 
data on its effects on HDL cholesterol, triglycerides 
and lipoprotein(a) is still somewhat conflicting.2,7,27 
One meta-analysis showed that the beneficial effects 
of  T4 therapy was proportional to the degree of 
hypothyroidism and the serum lipid level, such that 
reduction in serum lipids was significant in those with 
a TSH level >10m/IU/L and in those whose baseline 
serum cholesterol was >6.2mmol/L.3,9,15,27-28 However, 
other studies did not show any relationship between 
SCH and raised cholesterol levels.24,28  
 
Effects of replacement therapy 
When it comes to the effects of treatment on 
symptoms, hypothyroid symptoms tended to improve 
only when the TSH level exceeded 10mIU/L.29-30    In 
the Colorado study, patients with SCH reported more 
symptoms than euthyroid subjects but fewer 
symptoms than in the overtly hypothyroid patients.10    
Taking this into account, the available data does not 
confirm clear-cut benefits for routine thyroxine 
therapy in patients whose serum TSH level is 
<10mIU/L but serial monitoring of TSH levels at 6- to 
12-month intervals with a ‘watch-and-wait policy’ is 
prudent and instituting therapy if the TSH levels 
worsens or if the patient has symptoms compatible 
with hypothyroidism.2-3,9   
Subclinical hypothyroidism and pregnancy 
Another important issue to consider is the finding 
of SCH in pregnant women or those women 
contemplating pregnancy. The importance of thyroid 
hormone (especially in the first trimester) for foetal 
brain development and maturation is well known. 3,31 
It has been shown that the prevalence of SCH in 
women of reproductive age is  between 0.5-5%.3,6,10,17  
Trimester-specific reference ranges for TSH should be 
applied, this is because there is strong evidence in the 
literature to suggest that both the upper and lower 
normal limits of TSH levels are lower in the 
pregnancy state when compared to the non-pregnant 
state.32 Several studies have shown an association 
between SCH and increased risk of adverse pregnancy 
outcomes.  However, even here data is also 
conflicting. The commonly reported adverse effects 
include increased rates of miscarriages, placental 
abruption, preeclampsia and premature delivery.31,33-34  
One study found an association between inadequately 
treated women with SCH and foetal neurocognitive 
development.  This study (which mainly recruited 
overtly hypothyroid pregnancies) demonstrated a 
reduction in intelligence quotient as well as delays in 
motor, language and attention in off-spring of mothers 
with thyroid hormone insufficiency. Thus, the ATA 
taskforce state that the available high-quality evidence 
is enough to associate SCH with increased risk of 
adverse pregnancy outcomes.32    Overall, these data 
show that the potential benefits of levothyroxine 
treatment outweigh the risks in pregnant women and 
hence justify its use.   
 
Risks of replacement therapy 
Finally one should also keep in mind the risks of 
thyroxine therapy. It has been shown that around 50% 
of patients on thyroxine replacement have serum TSH 
levels either above or below the reference range, 
implying that a considerable number of patients are 
either under-  or over-treated.10,15,20 The consequences 
of over-treatment are iatrogenic hyperthyroidism 
which has been associated with two important adverse 
outcomes, namely osteopenia and atrial 
fibrillation.2,18,36  Two meta-analyses of cross-
sectional studies on postmenopausal women both 
found that suppressed TSH values with thyroxine 
treatment were associated with significant reduction 
in bone mass.  On the other hand, in the Framingham 
study, the risk of developing atrial fibrillation in 
patients with low serum TSH levels was increased 
threefold in subjects aged ≥60 years compared to 
those with normal TSH levels.8,20  Moreover, in 
elderly subjects with mild SCH, treatment is not 
always beneficial.3  As has been stated previously, 
mild increases in serum TSH levels in elderly subjects 
does not always imply true thyroid hormone 
deficiency and that mild thyroid failure may be 
associated with longevity.2,7 Studies have also shown 
that CHD events and mortality were lower in older 
patients with mild SCH.24 Hence, routine treatment 
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many authors and that treatment should be 
individualised based on the presence of associated co-
morbidities, symptoms, cognitive function and overall 
quality of life.3,7 When treating this cohort of patients, 
lower doses of thyroxine therapy are often adequate 
and clinicians should set higher target serum levels for 
TSH then in younger subjects in a bid to mimic 
physiological values.  
Another important issue to consider when 
contemplating thyroxine replacement in patients with 
autoimmune thyroid disease is hypocortisolaemia. 
The association of autoimmune thyroid disease and 
Addison’s disease is well described.  Thus, it is 
prudent to exclude adrenal insufficiency before 
starting thyroxine replacement in order to avoid a 
potentially fatal adrenal crisis.  Moreover, it has also 
been shown that adrenal insufficiency per se may be 
associated with raised TSH levels which normalise 
when glucocorticoid deficiency is corrected. 37 
 
Conclusion 
  SCH is a commonly encountered condition in 
clinical practice. However, as one can see the myriad 
of differences encountered in study results as well as 
the paucity of evidence in certain situations makes 
management of SCH somewhat difficult. Most 
authors advise use of clinical judgement as well as 
individualising management on a case-by-case basis.  
Until the availability of large, double-blinded 
randomised controlled trials upon which to base 
unequivocal recommendations, clinicians should base 
their management strategy on the underlying unique 
patient characteristics (such as age, gender, presence 
of hypothyroid symptoms, cognitive, metabolic and 
cardiovascular risk factors as well as quality of life) in 
order to have sufficient grounds for or against 
treatment.   
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